Posts tagged ‘imatinib’
EHA 2011 patient advocacy session missing two or three doses of CML therapy per month may have serious impact on outcome
June 16th, 2011
Daedalus
Have you ever failed to complete a course of antibiotics or missed the occasional dose of a cancer drug thinking it won’t kill you?
An interesting presentation by David Marin of the Hammersmith Hospital at the recent European Hematology Association (EHA) Congress in London highlighted how missing two or three doses per month of tyrosine kinase inhibitors for Chronic Myeloid Leukemia (CML) may have a dramatic effect on outcome.
Pieter Droppert on Biotech Strategy Blog has written more about the patient advocacy session at EHA 2011 where Dr Marin presented on CML adherence.
As Sally Church discusses on her EHA video blog, better patient and physician education is needed about adherence along with packaging of drugs that encourages compliance.
The take home is that even if you feel better, continuing to take a treatment may the right course of action in the long-term.
If you are interested in more information about CML adherence, then Jan Geissler, who chaired the EHA patient advocacy session, has posted more information on the CML Advocates Network website.
Photo Credit: Nimesh Madhaven
This Friday sees the start of the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. The meeting runs from June 3-7.
On Pharma Strategy Blog, Sally Church shares her thoughts on what she expects to be hot news at ASCO this year.
In her ASCO11 video preview Sally discusses clinical trial presentations in ovarian cancer, metastatic melanoma and soft tissue sarcoma. You can watch Sally’s video below and read more on Pharma Strategy Blog.
Icarus Consultants will be attending ASCO (along with 30,000 others), so if you are interested in meeting up, please contact us.
Sally Church’s interview with Dr Charles Sawyers rated a “must read” by Forbes Health
May 5th, 2011
Daedalus
Sally Church invests a lot of her personal time in writing for Pharma Strategy Blog. With a focus on the science of new products and treatments in cancer and hematology, Sally willingly shares her passion, knowledge and expertise.
It is always a pleasure to receive endorsement from others. Matthew Herper from Forbes Health kindly highlighted Sally’s interview with Dr Charles Sawyers as a “must read.”
We agree. Dr Sawyers is one of the leading translational scientists in the United States who along with Dr Brian Druker and Dr Nick Lydon received the prestigious Lasker award for their work on imatinib (Gleevec/Glivec) in CML. Dr Sawyers is now working on prostate cancer, and in his interview with Sally, describes his latest work developing MDV3100 and ARN-509.
We unequivocally recommend reading Sally’s post on Pharma Strategy Blog, “Making a difference to the lives of cancer patients: An interview with Dr Charles Sawyers.”
Published by Pieter Droppert on Biotech Strategy Blog
Published by Sally Church on Pharma Strategy Blog